Dr Reddy’s Q1 earnings may defy concerns around blockbuster cancer drug
Published on 17/07/2025 04:32 PM
Dr Reddy’s Q1 earnings may defy concerns around blockbuster cancer drugRevlimid – the key concern for Dr Reddy’s is due to the drug’s patent expiry in January 2026, paving the way for competition from generic makers and reduced prices.By Vipal Durge July 17, 2025, 4:32:53 PM IST (Updated)3 Min ReadHyderabad-based Dr Reddy’s Laboratories is expected to post positive top-line and profit figures in the upcoming first-quarter results scheduled for announcement on July 23. While some brokerages are bearish regarding the company’s ability to address revenue decline concerns from its blockbuster cancer drug, Revlimid, these won’t reflect in the first-quarter earnings this fiscal. Continue Reading with CNBC-TV18 Access MembershipPriority Access and Networking: CNBC-TV18's flagship events Interaction with CNBC-TV18's journalists Webinars & LIVE Q&As with India Inc. Leaders Exclusive CNBC-TV18 studio & newsroom tours Premium business insights, expert opinions & analysis Curated lifestyle privileges & offersBecome A Member